Last reviewed · How we verify

NCT06802874: PEG18

Maternal-fetal Outcomes of Genital Blood Loss Beyond 18 Weeks of Pregnancy

Recruiting now Last updated 31 January 2025
What this trial tests

trial in Blood Loss in 300 participants. Currently enrolling.

Timeline
15 November 2023
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment300
Start date15 November 2023
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across Italy

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

Adults 18 to 45, female only, with Blood Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to assess in terms of frequency the adverse outcomes (premature birth, maternal-fetal haemorrhage, maternal fetal-neonatal death) of pregnancies of women attending the obstetric-gynaecological emergency department for genital bleeding beyond the 18th week of pregnancy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Blood Loss

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06802874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing